Combination of mTOR inhibitor ridaforolimus and HDAC inhibitor vorinostat exhibits in vitro synergism in synovial sarcoma, osteosarcoma, and a range of other tumor subtypes

Abstract

Background: Curative treatments for patients with metastatic synovial sarcoma (SS) do not exist, and such patients have a poor prognosis. We explored combinations of molecularlytargeted and cytotoxic agents to identify synergistic treatment combinations in SS cells.

Methods: Two SS cell lines (HS-SY-II and SYO-I) were treated with single agents or combinations of molecularly targeted therapies (HDAC inhibitor, vorinostat; mTOR inhibitor, ridaforolimus) and cytotoxic agents. After 72 hours, cell viability was measured using the cell proliferation assay (MTS). Combination Indices (CI) were calculated to determine whether each combination was synergistic, additive, or antagonistic. The most active combination was selected for further confirmation in other tumor subtypes.

<u>Results:</u> Ridaforolimus IC₅₀ was 10.9 nM in HS-SY-II and 23.1 nM in SYO-I; vorinostat IC₅₀ was 440 nM in HS-SY-II and 561 nM in SYO-I; doxorubicin IC₅₀ was 9.4 nM in HS-SY-II and 7.4 nM in SYO-I; and melphalan IC₅₀ was 687 nM in HS-SY-II and 859 nM in SYO-I. Synergism was observed in cells treated with ridaforolimus/vorinostat: CI was 0.28 and 0.63 in HS-SY-II and SYO-I, respectively. Both ridaforolimus/doxorubicin and ridaforolimus/melphalan exhibited synergism: CI ranged from 0.50 to 0.59 in HS-SY-II and SYO-I. Additive effects were observed when vorinostat was combined with doxorubicin or melphalan. Given its strong synergism, the ridaforolimus/ vorinostat combination was assessed in osteosarcoma (U2OS, M189, and P16T), metastatic melanoma (Stew1 and Stew2), pancreatic cancer (Panc1 and BxPC3), and non-small cell lung cancer (A549) cell lines. The combination was synergistic in all cell lines: CI ranged from 0.37 to 0.77, except in Panc1, where it was additive (CI was 0.92).

Conclusions: The combination of ridaforolimus and vorinostat is synergistic *in vitro* in SS as well as in a variety of tumor types, including osteosarcoma, melanoma, pancreatic cancer, and nonsmall cell lung cancer. In anticipation of human studies, further in *vitro* studies are planned to assess the activity of this combination in other sarcomas subtypes and *in vivo*. Studies to assess the molecular basis for this synergism are also planned.

Background

 \succ STS is responsible for approximately 4,000 deaths in US in 2010.

 \succ At least 50 distinct histological STS subtypes exist.

> Unresectable or metastatic disease occurs in approximately 40-60% of patients, which portends poor prognosis.

 \succ First line treatment is doxorubicin, with typical response of 26%.

Curative systemic treatment options for patients with unresectable or metastatic STS are currently not available.

Effective systemic therapies are desperately needed to treat unresectable and metastatic STS.

Project Goal

Evaluate the *in vitro* sensitivity of synovial sarcoma cells to vorinostat and ridaforolimus alone and in combination with standard chemotherapeutic agents.

Sherif S. Morgan and Lee D. Cranmer

University of Arizona, Arizona Cancer Center, Tucson, AZ, USA.

Results

Table 1. The average calculated (and range of) IC₅₀ for each agent alone in HS-SY-II and SYO-I


Cell Proliferation Assay:

Cells were seeded in quadruplicate in 96-well plates at a density of 4.0 x 10³ cells per well for 24 hours followed by incubation with vehicle or drug for 72 hours. Cell viability was measured using the MTS CellTiter 96[®] AQ_{ueous} One Solution Cell Proliferation Assay (Promega).

Treatments Ridaforolimus Vorinostat Dalotuzumab Doxorubicin **Melphalan** Gemcitabine

Table 2. Summary of the combination index (CI) values for each treatment combination

| HS-SY-II | | | SYO-I | | |
|-------------|---------------|------------|-------------|---------------|------------|
| | Ridaforolimus | Vorinostat | | Ridaforolimus | Vorinostat |
| Vorinostat | 0.28 | n/a | Vorinostat | 0.63 | n/a |
| Doxorubicin | 0.56 | 1.1 | Doxorubicin | 0.50 | 0.98 |
| Melphalan | 0.51 | 0.91 | Melphalan | 0.59 | 0.90 |
| Gemcitabine | 3.1 | 1.54 | Gemcitabine | 2.6 | 2.25 |




CI = 0.9 - 1.1Additive

CI > 1.10 Antagonistic

Table 3. Combination of ridaforolimus and vorinostat in a panel of cell lines.

Cell Proliferation Assay was used to determine the effects of the combination of ridaforolimus and vorinostat in a variety of cell lines, including non-small cell lung cancer, pancreatic cancer, osteosarcoma, and metastatic melanoma. CI values for the ridaforolimus/vorinostat combination in these cell lines are presented here.





Conclusions

> The combination of ridaforolimus and vorinostat is synergistic in synovial sarcoma cell lines (HS-SY-II and SYO-I) as well as other cell lines (non-small cell lung cancer, pancreatic cancer, osteosarcoma, and metastatic melanoma).

> Ridaforolimus in combination with doxorubicin or melphalan is synergistic in both synovial sarcoma cell lines.

- > Vorinostat in combination with doxorubicin and melphalan is additive in both synovial sarcoma cell lines.
- > Gemcitabine antagonizes the effects of ridaforolimus and vorinostat in synovial sarcoma cell lines (HS-SY-II and SYO-I).

| HS-SY-II | SYO-I |
|---------------------------------|---------------------------------|
| 10.9 nM (2.1 to 23 nM) | 23.1 nM (3.4 to 33.2 nM) |
| 440 nM (216 to 612 nM) | 561 nM (341 to 702 nM) |
| Indeterminate* | Indeterminate* |
| 9.4 nM (5.98 to 14.8 nM) | 7.4 nM (3.1 to 16.2 nM) |
| 687 nM (432 to 1227 nM) | 859 nM (401 to 1472 nM) |
| 2.6 nM (2.1 to 2.9 nM) | 2.4 nM (0.9 to 3.43 nM) |

Calculation of Combination Index (CI) values:

CI was calculated using the median-effect analysis method of Chou and Talalay.

| CI | = | D ₁ + | D ₂ |
|----|---|--------------------------------|--------------------------------|
| 0. | | (D _x) ₁ | (D _x) ₂ |

where D_1 and D_2 are doses of drugs 1 and 2 that have x% effect when used in combination, and $(D_x)_1$ and $(D_x)_2$ are doses of drugs 1 and 2 that have the same x% when used alone as single agents.

| Disease | CI |
|----------------------------|---|
| Non-Small Cell Lung Cancer | 0.54 |
| Pancreatic Cancer | 0.92 |
| Pancreatic Cancer | 0.50 |
| Osteosarcoma | 0.56 |
| Osteosarcoma | 0.59 |
| Osteosarcoma | 0.77 |
| Metastatic Melanoma | 0.46 |
| Metastatic Melanoma | 0.37 |
| | Non-Small Cell Lung CancerPancreatic CancerPancreatic CancerOsteosarcomaOsteosarcomaOsteosarcomaMetastatic Melanoma |

150-7.



THE ARIZONA CANCER CENTER

Melanoma/Sarcoma Program

Discussion

> Synergy between ridaforolimus and vorinostat *in vitro* appears very promising.

> Synergistic and additive effects of ridaforolimus or vorinostat with cytotoxic chemotherapies (e.g. doxorubicin) may have clinical relevance.

- Ridaforolimus or vorinostat may serve as a chemotherapy-sparing agent, reducing the dose-limiting toxicities associated with a particular agent.
- This may be especially important with doxorubicin, a backbone therapy for STS, but hampered by doselimiting cardiotoxicity.

Future Directions

Determine whether the combination of ridaforolimus/ vorinostat is synergistic in other STS subtypes.

2. Determine the effects of ridaforolimus/vorinostat combination. compared to single agents, in an in vivo STS mouse model.

3. Characterize the molecular mechanisms that mediate the synergistic effects between ridaforolimus and vorinostat.

4. Determine the effects of this combination in STS patients.

References

Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 2006. 58(3):621-81.

Van Glabbeke, M., et al., *Prognostic factors for the outcome of* chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft *Tissue and Bone Sarcoma Group Study.* J Clin Oncol, 1999. **17**(1): p.

Weitz, J., C.R. Antonescu, and M.F. Brennan, Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over *time.* J Clin Oncol, 2003. **21**(14): p. 2719-25.

Wunder, J.S., et al., *Opportunities for improving the therapeutic ratio for* patients with sarcoma. Lancet Oncol, 2007. 8(6): p. 513-24.

Acknowledgements

We would like to acknowledge Merck for providing ridaforolimus and vorinostat. This research was supported, in part, by the Phoenix Friends of the Arizona Cancer Center Scholar Award.

Please scan this QR code to download a copy of this poster or to contact us

